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Optical Detection of Degraded 
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The quality of therapeutic proteins such as hormones, subunit and conjugate vaccines, and antibodies 
is critical to the safety and efficacy of modern medicine. Identifying malformed proteins at the point-
of-care can prevent adverse immune reactions in patients; this is of special concern when there is 
an insecure supply chain resulting in the delivery of degraded, or even counterfeit, drug product. 
Identification of degraded protein, for example human growth hormone, is demonstrated by applying 
automated anomaly detection algorithms. Detection of the degraded protein differs from previous 
applications of machine-learning and classification to spectral analysis: only example spectra of 
genuine, high-quality drug products are used to construct the classifier. The algorithm is tested on 
Raman spectra acquired on protein dilutions typical of formulated drug product and at sample volumes 
of 25 µL, below the typical overfill (waste) volumes present in vials of injectable drug product. The 
algorithm is demonstrated to correctly classify anomalous recombinant human growth hormone (rhGH) 
with 92% sensitivity and 98% specificity even when the algorithm has only previously encountered 
high-quality drug product.
The use of therapeutic proteins has become common practice in medicine and their success has stimulated sig-
nificant investment towards the discovery and manufacture of a wide range of biopharmaceuticals. A central 
challenge of protein therapies is the potential to trigger antibody formation. Triggering such an immune response 
has consequences for both the efficacy of the therapy and the safety of the patient1,2. Several factors have been 
correlated to immunogenicity: these include impurities, such as protein aggregates3, differences in glycosylation, 
deamidation or oxidation4,5, and protein misfolding6.
Rapid quality assessment of therapeutic proteins is essential when there is the possibility of an insecure sup-
ply chain – resulting in the shipment of degraded proteins or in the sale of counterfeit products – or when there 
is a need to closely monitor and control biopharmaceutical manufacturing. Formulated proteins require cold 
distribution and storage, a major limiting factor for treating populations in rural and developing areas. In India, 
concerns about spoilage necessitate preventative measures such as discarding vaccine vials that have been distrib-
uted to three vaccination clinic events, even if the vials remain unopened, resulting in a vaccine wastage rate of 
roughly 60%7–10. Despite these policies, a study looking for freeze events during distribution found that up to 76% 
of the vaccine vials tested showed evidence of spoilage due to freezing11. Point-of-care applications are especially 
challenging as a quality determination must be made rapidly on small sample volumes in clinical settings that 
may be resource constrained.
The above immunogenic factors all involve changes in the molecular characteristics of the protein that may be 
possible to measure at the point of care using Raman spectroscopy. Here we present a Raman instrument capable 
of measuring proteins in solution at dose relevant concentrations and with a sample volume small enough that it 
could be taken from the overfill volume used in vial packing of drug products12, and demonstrate a classification 
technique that is capable of identifying degraded material based on changes in the scattered Raman spectrum.
Raman spectroscopy, discovered in 1928 by C.V. Raman and K.S. Krishnan13, is commonly used in the analysis 
of biological materials14 and has been used for the verification of primary and secondary structure of proteins since 
195815–17. The published examples of protein Raman spectra have typically been reported for solid powders and for 
solutions with concentrations in excess of 5 mg/mL, higher than many formulated products. Previous work has been 
limited to high protein concentrations because of the small cross-sections for Raman scattering coupled with the 
potential for photo-degradation of the protein under high illumination. Traditionally, to detect proteins at lower, 
dose-relevant, concentrations has required a switch to Surface Enhanced Raman Scattering (SERS).
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Surface Enhanced Raman Scattering is a technique where the protein is adsorbed to a metallic substrate, 
resulting in resonance enhancement of the excitation field18–20. The resonance enhancement enables detection 
down to the single molecule level20. The SERS signal is related to the constituent amino acids and amide back-
bone of the protein21,22, but the spectrum differs from the spectra of the protein in solution due to the fact that 
the SERS technique is sensitive to the orientation of the adsorbed protein23. Therefore, if the orientation of the 
protein cannot be controlled there will not be a unique spectrum associated with any given protein when using 
SERS. Additionally, this technique requires a consumable substrate with a limited shelf life24,25. Fortunately these 
complications can be avoided as several therapeutic proteins are provided in formulation at concentrations high 
enough that the signal enhancement from SERS is not needed. Here we show that characterization of these pro-
teins is possible using spontaneous Raman spectroscopy of free-proteins in solution, provided the sample holder 
and optical system are well designed. Our approach was to employ the double-pass, confocal optical geometry 
illustrated in Fig. 1b, with a sample volume of approximately 25 µL. This sample volume is smaller than the U.S. 
Pharmacopeia recommended excess volume (overfill) of 100 μL for injections supplied in vial form with a label 
size of 0.5 mL and larger, so it would be possible to operate the system using the overfill volume present in these 
products12.
Alongside the Raman instrument reported here, we have developed a classification algorithm that is capable 
of classifying a protein that has degraded. While automated classification algorithms have been widely used for 
spectral classification26–30, the challenge here is to develop a classifier that can detect a myriad of degraded pro-
tein forms that that the algorithm has never encountered before. This is a specific case of the general One Class 
Classification problem in chemometrics31. In this problem, there is a large set of data in one class, and a limited or 
non-existent set of data in the ‘other’ class. This problem occurs in a number of domains with examples including 
anomaly detection in gas turbines32 and classification of documents as relevant to a user33. One class classification 
has been applied for Raman spectroscopy based identification of unknown bacterial strains34 and the detection 
of simple mixtures of chlorinated solvents35. This work expands the technique to the Raman spectral analysis of 
complex molecules with a particular focus on therapeutic proteins.
We demonstrate two different approaches to training the classification algorithm using only “good” protein 
spectra. In both cases the goal is to train the classifier so that it ignores systematic variations associated with 
the instrument such as shot noise, alignment drift, etc. and instead focuses on spectral features that are corre-
lated with the protein analyte. In the first approach the algorithm is trained using only spectra from high-quality 
Figure 1. (a) The US pharmacopeia recommends that therapeutics supplied in a vial have some amount of 
overfill (excess) volume in the package to allow a complete dose to be drawn from the vial. Our sample holder, 
shown in (b) is designed with a sample volume of 25 µL, which is lower than the 100 μL overfill recommended 
for any drug product delivered in a vial 0.5 mL or greater. The total volume is kept low by recognizing that 
the volume of sample directly illuminated by the excitation light will produce most of the collected Raman 
signal. The depth of the sample holder was set so that the microscope objective used in this system, a Nikon 
Plan Fluorite 40 × 0.75NA objective, could focus on the mirror at the back of the sample holder. A schematic 
diagram of the Raman system beyond the sample holder is shown in (c). The raw signal for a protein in a buffer, 
the buffer, and the reconstructed protein spectrum (magnified 10×) is shown in (d). For the concentrations 
and samples examined here, the Raman signal has significantly lower intensity than the raw signal requiring 
careful background subtraction to retrieve the protein Raman signal. (e) Protein spectra from the four proteins 
examined during this project. To gauge the repeatability of the system several spectra were taken of rhGH over 
a year long period at a fixed concentration and spectra of Insulin over a three month period across a range of 
concentrations as indicated in (e). All spectra are plotted after normalization.
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recombinant human growth hormone (rhGH) and in the second approach the training uses both the high-quality 
rhGH and spectra from three unrelated high-quality proteins of various sizes. The addition of the different pro-
tein spectra improves the algorithms ability to identify the protein variants and the algorithm is demonstrated to 
correctly classify degraded recombinant human growth hormone (rhGH) with 92% sensitivity and 98% specific-
ity for the range of degraded and un-degraded samples used for this work.
Methods
Spectra Acquisition. Raman spectra were collected using a purpose built system, shown in Fig. 1c, designed 
around the low volume sample holder illustrated in Fig. 1b. The sample holder featured a 100 µm thick fused 
silica sampling window used for both excitation and collection of the Raman signal. A microscope objective 
was used to focus the excitation light and collect the Raman scattered light. A gold mirror at the back plane of 
the sample holder, positioned near the focal point of the microscope objective (NA = 0.75, 40x magnification), 
increased the excitation energy by redirecting the excitation light back through the sample and increased the 
system’s Raman signal collection by redirecting forward scattered Raman light back towards the microscope 
objective for collection.
Recognizing that the Raman signal will be collected primarily from the region close to the focus of the micro-
scope objective, the dimensions of the liquid containing well were set at 4 mm wide, 6 mm long, and 0.8 mm deep 
along the optical path for a total volume of approximately 19 µL. The sample holder did not need to be any larger 
than this because the increased sample volume would not improve the amount of sample-laser interaction and 
the walls and mirror in the sample holder were metallic, so they added no background Raman signal. The depth 
of the sample holder was set to allow the microscope objective to focus light on the back mirror to achieve an 
increase in excitation and collection as described above, while at the same time moving the excitation spot as far 
from the fused silica window as possible to reduce the background signal from the window.
To use the holder a 20–25 µL drop of material was added to the well, over filling it slightly, and then the 
well was capped with the mirror. This prevented the formation of an air bubble between the sample and mirror, 
resulted in a consistent sample volume and geometry with no meniscus, and effectively sealed the sample pre-
venting it from drying during long spectrum acquisitions. The inverted configuration ensured that neither the 
sample holder nor the microscope objective needed to move during sample loading or cleaning operations. This 
allowed the system to be used without re-aligning the optics each time a new sample was presented to the system.
Sample volumes down to 1 μL are possible with capillary based sample holders36 but these have an unavoidable 
overlap of the excitation laser with the capillary walls resulting in a significant background signal due to the cap-
illary material and an attenuation of the excitation light due to scattering or absorption by the capillary material. 
The impact of the background signal due to the capillary material can be mitigated by choosing a material with a 
small Raman cross section such as Teflon, but this approach has not been shown to improve the protein limit of 
detection37.
The excitation laser used with this system was a fiber coupled Ondax laser operating at 830 nm (R0-830-PLR-
300-MM-1) delivering approximately 100 mW of laser power to the sample. Light was delivered from the laser to 
collimating optics via a 105 μm core multimode fiber. The collimated light was passed through a Semrock 830 nm 
MaxLine Laser clean-up filter to remove any amplified spontaneous emission from the laser and any Raman light 
generated within the delivery fiber. The filtered light was coupled into the optical path of the microscope objective 
by a Semrock long pass filter operated as a dichroic mirror. Collected light was passed back through the Semrock 
filter and then through an additional long pass filter to further attenuate Rayleigh scattered excitation light before 
being coupled into a fiber bundle for delivery to the spectrometer. A diagram of the system is given in Fig. 1c.
Spectra were acquired using an Acton SP-300i grating spectrometer. The use of a mirror in this sample holder 
does significantly increase the amount of Rayleigh scattered light collected by the system. To prevent the scattered 
excitation light from saturating the detector the grating in the spectrometer was adjusted to position the scattered 
excitation light off of the sensor. To generate the spectra presented here the following procedure was used. For 
each sample of protein solution, 100 spectra were collected with an integration time of 10 s per spectrum. Cosmic 
ray events were identified in the 10 s spectra and removed. After cosmic ray removal, the individual spectra were 
scaled to match the median value of pixels 200 to 300 across the 100 spectra set to account for variation in the 
laser power. This region was chosen because it was beyond the filter turn on region and generally contained no 
strong spectral peaks. The individual 10 s spectra were then smoothed across wavelength using the Savitzky-Golay 
filter function (Matlab) with a degree of 11. A representative sample spectrum was created by taking the mean 
value of the 100 filtered and smoothed spectra at each wavelength, and a noise spectrum was created for each 
measurement by taking the standard deviation at each wavelength across the sample spectra.
The sample spectrum resulting from this processing contained Raman and fluorescence signal from the pro-
tein, sample holder, and the buffer that made up the bulk of the protein solution. A characteristic background 
spectrum for each protein buffer was created using the process described above but with the appropriate buffer 
solution rather than a protein sample. The characteristic background spectrum for the rhGH buffer is shown in 
Fig. 1d with a 10x magnified Raman spectrum of rhGH for comparison. To generate the protein Raman spectra 
presented in the results section this characteristic background spectrum was subtracted from the sample signal 
and any residual fluorescence was removed by performing a positive residual style polynomial subtraction as 
described in ref.38. Calibration of the Raman shift was performed using a polystyrene sample with a well-known 
Raman spectrum.
Protein material preparation. The proteins used in this experiment were obtained from several suppliers. 
Somatropin, recombinantly produced human growth hormone (rhGH), was obtained from Sandoz supplied in 
10 mM sodium phosphate buffer at a pH of 7.0 and a concentration of 10.7 mg/ml. This material was frozen and 
stored at −20 °C for shipping, thawed for aliquoting, and the aliquots stored at −80 °C before being thawed for 
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use. The interferon was obtained from RayBiotech (228-10819-3) as a lyophilized powder from a 1 mg/ml solution 
containing 2.3 mg Sodium phosphate dibasic and 0.55 mg sodium phosphate monobasic buffer and reconstituted 
in distilled water at a concentration of 3.5 mg/ml. The interferon was used directly after reconstituting to avoid the 
potential damage of a freeze-thaw cycle. The Immunoglobulin-G (IgG) was obtained from Bethyl Laboratories 
(P80-105), purified from serum and at a concentration of 1 mg/mL. The IgG was supplied in phosphate buff-
ered saline containing 0.09% sodium azide. Lyophilized insulin powder was obtained from Sigma (I2643) and 
reconstituted in a 0.01 N HCl solution at a maximum concentration of 11 mg/ml. The proteins examined here 
were supplied in, or reconstituted into, variants of Phosphate Buffered Saline (PBS) except for insulin which was 
reconstituted in 0.01 N HCL. Drug product buffers may contain sugars or similar molecules with unique Raman 
signatures but here we maintained similar buffers where possible to allow for direct comparison of the limits of 
detection and to avoid buffer exchange.
A series of oxidized human growth hormone samples were prepared from reference material in order to exam-
ine the sensitivity of the instrument to changes in proteins due to degradation processes. The oxidized samples 
were generated by exposing Sandoz Somatropin to 5% hydrogen peroxide (Sigma) and then incubating the mate-
rial at 37 °C overnight. This resulted in varying levels of oxidation of the Methionine groups M14, M125, and 
M170. A summary of the oxidation levels of the sample material is given in Table 1, and the oxidation sites are 
illustrated in Fig. 2(a).
Liquid Chromatography - Mass Spectrometry of Oxidized Human Growth Hormone. To prepare 
the reference and oxidized rhGH samples for LC-MS they were first fragmented into peptides and transferred 
from their original buffers to a buffer suitable for LC-MS. The first step in fragmenting the proteins was to dissolve 
the samples in 6 M Guanidinium chloride to denature the proteins. The disulfide bonds within the proteins were 
then broken by a reduction step using 10 mM dithiothreitol (DTT) at 70 °C for 30 minutes followed by an alkyla-
tion step using 55 mM iodoacetamide (IAA) at room temperature for one hour in the dark.
In preparation for digestion, the proteins were then dialyzed three times in Tris-HCl buffer, pH at 6.8, via 10 
kD Amicon membrane centrifugal filters (Millipore, Merck, Germany) at 12,000 rpm for 15 minutes. The proteins 
were then digested with Trypsin at room temperature overnight to fragment the proteins into peptides while 
minimizing artificial oxidation. The digestion process was terminated with 20 µL 5% formic acid and the peptide 
solutions were aliquotted to 20 µL samples and stored at −80 °C for further analysis.
A Dionex 3000 UPLC system (Ultimate 3000, Sunnyvale, CA) was used for the liquid chromatographic sepa-
ration and a Thermo LTQ XL (Linear Ion Trap, Thermo, San Jose, CA) was used for the mass spectrometry. The 
liquid chromatographic separation used a self-packed capillary column with an internal diameter of 75 μm and 
a length of 150 mm packed with Magic C18 (3 μm particle, 200 Å pore). The LC separation method was carried 
out by a 75 minute gradient elution program, using 0.1% formic acid in water as Phase A and 0.1% formic acid in 
acetonitrile as Phase B, at a flow rate 200 nL/min. The ratio of Phase B was increased from 2% to 40% over the first 
50 minutes, then increased to 95% over the next 5 minutes and kept there for 10 minutes. The ratio of Phase B was 
then decreased from 95% to 2% in 2 minutes and maintained at 2% to the end of the program.
The coupled linear ion trap mass analyzer was operated in the data-dependent CID fragmentation mode and 
it was adjusted automatically between MS and MS/MS acquisition in nine cycles with a full scan mode at m/z 
300-2,000 Da. Thermo Proteome Discover 1.4 was used to analyze the raw data, using a human growth hormone 
sequence database file and assuming full trypsin specificity. The tolerance for precursor ions was set at 50 ppm 
and the tolerance for product ions was set at 1.0 Da. Carbamidomethylation of cysteine was selected as a static 
modification and deamidation on asparagine and oxidation on methionine were selected for dynamic modifica-
tion search. The final confirmation of the modifications was by manual search.
Classification of Protein Variants. The goal of this work was to develop a classifier capable of recognizing 
if a particular sample under test was high-quality rhGH or degraded rhGH. A standard binary classifier could be 
developed for this problem with an output of either “good material” or “bad material”. The standard classification 
algorithms for this problem work by defining a boundary between the two classes, based on examples from each 
class. These algorithms assume that the samples presented to the classifier adequately sample the space of possible 
spectra generated by each class. However, in this application a complete set of “bad” examples does not exist, the 
range of degraded products is too large to adequately sample, and instead the classifier must define the boundary 
with only examples of the “good” class. This problem falls into the general field of one-class classification39. A vari-
ety of classifiers including Support Vector Machines40,35, neural networks33, and nearest-neighbors41 have been 
applied to this problem. The approach used in this paper will be to define an ellipsoid in N dimensions (where N 
Sequence
Control 
Samples
Degraded 
Samples
Oxidized Material 
With CD Spectra
M14 (ox.) LFDNAMLR 3 to 14.2% 40 to 100% 90%
M125 (ox.) DLEEGIQTLMGR 3 to 1.6% 12 to 100% 100%
M170 (ox.) DMDKVETFLR 5 to 0.1% 3 to 90% 90%
N149 (deamid.) FDTNSHNDDALLK 0 to 3% 3 to 90% 3%
Table 1. Oxidation and deamidation summary. This table summarizes the oxidation at methionine sites M14, 
M125, and M170 and the deamidation at site N149 in the oxidized and stability test samples. The samples were 
generated and characterized by the Hancock lab at Northeastern University.
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is the size of the spectrum for classification), making the classifier presented a variant of the Minimum Volume 
Ellipsoid approach developed by Rousseuw42–44.
Given the high dimensionality of the data (1340 spectral data points in the raw data) and the small number 
(5) of repeated experiments generated degraded samples overfitting in the classifier is an important concern. 
Information about protein structure and condition is not uniformly distributed in the spectrum of the protein, so 
the first step after spectral processing is a dimension reduction to reduce the impact of spectral variation in low 
information regions on the classification algorithm. After background subtraction and residual polynomial fitting 
the first step in dimension reduction is to truncate the spectrum to an appropriate spectral region. The region 
from 800 to 1721 cm−1 was chosen because it contains the brightest features associated with protein structure 
and composition, resulting in a sample spectrum represented by a vector 830 points long. The data is then scaled 
into the region 0-1, to reduce the impact of small changes in concentration. The next step is to apply Principal 
Component Analysis (PCA) to further reduce the dimensionality of the data. The PCA algorithm finds a set of 
vectors in the original space that can be used to represent the data. The vectors are ranked by the amount of varia-
tion in the original data each vector captures. By using a set of principal components smaller than the dimension 
of the original space, the length of the vector representing each data point is reduced. Additionally, if the data set 
for the PCA algorithm is chosen correctly then the principal components themselves should be directly related to 
spectral information relevant to classifying the proteins.
Two methods of performing the initial principal component analysis for dimensionality reduction were inves-
tigated. In Method 1 the PCA algorithm was applied to a one set of spectra of the high-quality (un-degraded) 
rhGH. In Method 2 the spectra for the high-quality rhGH were combined with spectra from the three other 
high-quality proteins. The high-quality rhGH training set was formed from five data sets collected over the course 
of the year. As part of this research the impact of the number of data sets included in the training set was investi-
gated. In both Method 1 and Method 2, the N-highest ranked principal components were used to form a reduced 
dimensional space, and the test data was projected into this space. N was chosen such that the resulting PC space 
captured at least 60% of the variation in the training set. This reduced dimension data set was used as the input 
to the classifier.
The classifier examined here is constructed by defining an ellipsoidal surface that encloses the spectra rep-
resenting the high-quality rhGH material. The ellipsoid is chosen to follow the shape of the high-quality rhGH 
material and the resulting classifier can be written from the equation of an ellipsoid in N dimensional space as
Figure 2. (a) Visualization of the sites of potential degradation in human growth hormone. Of particular 
importance are the methionine residues which each contain a sulphur atom capable of forming a sulfoxide 
bond. (b) Control rhGH in red and degraded rhGH in cyan. The degraded material shows significant, but 
variable, differences when compared with the control material. (c) Circular dichroism spectra for the reference 
and one sample of highly oxidized human growth hormone, indicating no significant change in the helical 
portion of the protein under oxidation. (d) Raman spectra for the same material in (c), presented as counts in 
10 s, normalized by concentration.
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where x = (x1, …, xN) is the representation of the spectrum in the N dimensional space generated after the first 
round of PCA, σ is the vector representing the ellipse axes lengths, and Θ is a tuning parameter which controls 
the size of the ellipse. ⊘ is the Hadamard division operator indicating element-wise division of two vectors. 
The term (Ax − c) uses a projection matrix A and centroid vector c to project the data from the N-dimensional 
PC-projected space into an N-dimensional space centered on the classification ellipsoid with its coordinate axes 
aligned with the ellipsoids axes. A second round of PCA is performed using just the rhGH training data to define 
the matrix A, centroid vector c, and axis length vector σ. In this round the principal components now form the 
axes of the ellipse and set the projection matrix, A, the eigenvalues are used to set the relative size of the ellipse 
along each axis, σ, and the centroid of the projected high-quality rhGH spectra, c, is used to shift the projected 
data into the center of the ellipse. In this way the longest dimension of the ellipse will be aligned with the direc-
tion in which the un-degraded rhGH spectra are most spread, and the shortest dimension will be aligned with 
the direction in which the data are least spread. The performance of this classifier depends on the value of Θ. As 
a sample independent approach, the value of Θ can be set so that the classification ellipsoid captures 99% of the 
training examples.
Results
The characteristic spectrum of four proteins is shown in Fig. 1e. Each spectrum in the figure represents one 
1,000 second measurement (100 × 10 s spectra as discussed previously). These spectra are consistent with those 
reported in previous work at high concentrations and larger sample volumes16,45–47. A detailed peak assignment 
and interpretation is given in the supplementary material. To gauge the repeatability of the system several spectra 
were taken of rhGH over a long time period at a fixed concentration and of Insulin over a short time period with 
a variable concentration as indicated in Fig. 1e.
Protein Oxidation. Oxidized human growth hormone was prepared and analyzed by mass spectrometry, 
circular dichroism spectroscopy, and by Raman spectroscopy. A summary of the mass spectrometry analysis is 
given in Table 1, the Circular Dichroism result in Fig. 2c, and the Raman spectra of the highly oxidized protein is 
presented in Fig. 2d.
Figure 2b shows the Raman spectra of the degraded material along with the spectra of the control material. 
The spectra of the degraded material show large changes in the Raman response. To verify that there were no 
gross changes in the structure of the protein a set of circular dichroism spectra were taken of the most highly 
oxidized material and control material using a Circular Dichroism Spectrometer (Aviv Model 202). The CD spec-
tra, normalized by sample concentration as measured using UV-Vis absorption (NanoDrop A280), are shown in 
Fig. 2c. Circular Dichroism spectrum of the control and oxidized human growth hormone are consistent with an 
α-helix protein structure. A change in the circular dichroism spectrum of the protein would be expected if the 
helices of the protein were unfolding due to the oxidation process, but the experimental spectra show no change 
between the highly oxidized and control material. This indicates that there is no major change in the α-helix seg-
ments in the rhGH. However, human growth hormone is only about 45% α-helix48. The changes in the Raman 
spectra may be due to structural changes in the non-helix regions of the rhGH in addition to changes due to the 
chemical process of oxidizing the Methionine residues. Currently the changes in the Raman spectra do not result 
in a quantifiable measurement of protein oxidation, the changes are too large and too variable to be directly tied 
to protein oxidation. Rather than trying to produce a quantifiable measure of oxidation an alternate approach was 
pursued, developing a classifier to give a binary measure of the protein as either “good” or “bad”.
Protein Variant Classification. Two variations of the classification scheme outlined in the methods section 
were examined: one which uses only spectra from rhGH to define the classification boundary (Method 1) and 
one which also includes spectra from independent high quality proteins in the first step of dimension reduction 
(Method 2). In both approaches there are three parameters that can be adjusted to control the performance of 
the classifier: the number of rhGH spectra included in the first round of PCA, the size of the first PC space, and 
the relative size of the classification ellipse which is controlled by the tuning parameter Θ. The number of rhGH 
spectra included in the first round of PCA was kept variable to examine how the performance of the classifier 
changed as the amount of information about the high-quality rhGH increased while the other two parameters 
were set as discussed below.
The size of the first PC space can be set by making a decision about how much variation in the input data 
should be captured in the PCA. The eigenvectors associated with each principal component can be used as a 
proxy for the amount of variation in the original training data captured by each principal component. The higher 
this parameter is set, the more principal components will be required to represent the data. Aiming to capture 
~60% of the variation in the first input set results in a PC space of 9–30 components, representing a significant 
reduction in dimensionality while maintaining most of the variation in the data. The size of the classification 
ellipse was set so that the classifier identified 99% of the test data set as “good” material using the assumption that 
the classifier should at least be able to identify the training set as “good” material.
With N set to capture 60% of the training data variation and Θ set so that the classification ellipse encloses 
99% of the training set, it is possible to compare the results of the two methods of generating the first princi-
pal component space. Figure 3 shows the principal components that result from performing the first round of 
PCA on either just rhGH data (3a), or rhGH data along with additional non-rhGH data (3c), along with a spec-
trum of rhGH for comparison. While both methods produce principal components with some peaks at locations 
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associated with features in the proteins, the principal components produced when using information from addi-
tional proteins show more clearly defined features around regions that have been identified as having information 
about protein structure and composition.
As expressed in Equation 1, the classifier reduces the entire spectrum to one number, f(x), and then com-
pares that number with a threshold value. Figure 3b,d show the histograms of f(x) for the high-quality (red) and 
degraded (blue) samples under both methods for the case when the training rhGH set contains three of the five 
high-quality rhGH data sets. The dashed line in both figures indicates the decision threshold value Θ, with mate-
rial to the left of the dashed line identified as “good” and the material to the right of the line identified as “bad”. 
Under both methods the majority of the “good” reference material is identified as good because the value of Θ 
was chosen to pass 99% of the training set and because the variability among the good rhGH data sets was small. 
On the other hand, from the histograms it’s clear that the variability of the degraded material is fairly large, with 
some fraction appearing as quite similar to the “good” material and some appearing as quite distinct. In fact, from 
Figure 3. First principal components along with rhGH spectra for method 1, use only rhGH spectra, in (a) and 
for method 2, use spectra from all four proteins in (c). Histograms of the good and degraded materials along 
with classification boundary are shown in (b) for method 1, and in (d) for method 2. The red bars represent 
spectra from the reference high quality rhGH and the blue bars represent spectra from the degraded proteins. 
The “good” and “bad” labels indicate the decision of the classifier. Sensitivity (e) and selectivity (f) are shown for 
both methods as a function of the number of datasets used in training the classifier. This is with the algorithm 
set to capture 60% of the variation in the first round of PCA and 99% of the training data when setting the 
tuning parameter, Θ. As the size of the training set becomes larger, the classification ellipse must also become 
larger to continue capturing 99% of the training set. This generally results in an improvement in the specificity, 
but a decrease in the sensitivity of the classifier.
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the histograms it appears that the degraded material comes from a few discrete sets of possible degraded material 
justifying our assumption that we did not fully sample the space of possible degraded material.
To explore the performance of the classifier as the amount of information available increases the number of 
training examples to use in the first round of PCA was varied, using one, two, three, four, or all five sets of spectra 
collected over the course of a year. The bar charts in Fig. 3 shows how the sensitivity (3e) and specificity (3 f) vary as 
the number of spectra used during the first round of PCA increases for both Method 1 and Method 2. The reported 
sensitivity and specificities are the average across all possible combinations of spectra (5 combinations for using one 
or four sets of data, 10 for using two or three sets of data, and 1 for using all five sets of data). The specificity of the 
algorithm, its ability to identify non-degraded rhGH as “good”, improves as the number of data sets used to train the 
algorithm increases since the algorithm is set to capture 99% of the training data when setting the tuning param-
eter Θ. Since capturing more of the data requires a larger ellipsoid, the sensitivity of the algorithm in identifying 
degraded material as degraded decreases as the set of training data becomes larger. This is partially the result of some 
of the degraded material having spectra very similar to the non-degraded material. A good balance for this data 
set is obtained by using three of the five datasets in the training process. The sensitivity of the classifier, its ability to 
correctly identify degraded material, is significantly improved when the first round of PCA incorporates non-rhGH 
proteins. This is likely because of the fact that principal components are chosen to be vectors that represent change 
in the set of spectra used to generate them. In Method 1, training with just rhGH, the highest ranked principal com-
ponent matches the feature that changes the most among the set of “good” rhGH. Since all of the inputs are “good” 
rhGH this vector shouldn’t map to a physical feature in the protein since that feature should be common to all of 
the samples. In Method 2, training with rhGH and other proteins, to describe the variation among the proteins the 
principal components must describe the features in the protein that change between the different protein samples. In 
this way the inclusion of other proteins should bias the first step of the algorithm to generate principal components 
that have strong features at positions associated with protein structure since the set of spectra used to generate the 
principal components has significant variation in this features.
Discussion
The classification system discussed here can provide a binary judgment on the quality of a protein drug product 
without requiring the operator to interpret the spectrum of the protein. From the point of view of the end user 
they place a small drop of material into the system and get a “probably good” or “probably bad” indication. This 
basic approach allows such a system to be deployed in a point of care application since it does not require any 
expertise on the part of the user to evaluate the data, and only requires the ability to dispense a small sample of 
drug product. Physically, the current system takes the form of a large bench-top instrument but it is possible to 
reduce the size to something approaching a shoebox allowing deployment beyond clinical locations. As devel-
oped here, the system does have some limitations.
Currently the system relies on example spectra from “good” proteins at the correct concentration to form its 
classification boundary and can separate the “good” from “bad” proteins with reasonable accuracy on the set of 
good and degraded proteins examined here. Due to the pre-processing scaling of the Raman spectra into the 0–1 
range the classifier is insensitive to small changes in protein concentration. However, a change in concentration 
can signal that the drug product being tested is not the correct formulation or has undergone some degradation 
process. Monitoring the scale factor or testing using a UV absorption measurement to verify the protein concen-
tration should be done as part of the drug quality check. The algorithm presented builds a model for “good” pro-
teins based on examples of the good protein. This must be done separately for each drug product to be evaluated 
by the system, and then in use the system must be told what drug it is examining. Finally, the data presented here 
represent a fairly small set of both high quality and degraded drug product. In terms of oxidation, summarized in 
Table 1, the control material had up to 14% oxidation at methionine 14, while the degraded material samples start 
at 40% oxidation at that methionine residue. The results from this data are promising, but further work will be 
required to verify that the approach works across a larger range of control and degraded material and to examine 
how the algorithm responds to smaller changes in the protein.
Conclusions
Characterization of proteins at or below their therapeutic dose concentration within the correct buffer has 
numerous applications ranging from process analytics during the manufacture of bio-therapeutics to point of 
care applications where the quality of a protein can be checked before being administered to a patient. The system 
presented here can make repeatable spectral measurements of proteins at relevant concentrations and the clas-
sification algorithm can be used to identify “good” proteins without having to sample the entire space of “bad” 
proteins. Point-of-care applications benefit from the small sample volumes (25 μL) utilized for these experiments, 
which is small enough that it could be taken from the “overfill volume” used to ensure that a syringe can withdraw 
a full dose from a vial12. This approach allows testing of both the batch and single dose of the drug even in cases 
when the cost of sacrificing even a single dose is prohibitive, and will allow a hospital or clinic to identify drugs 
that have degraded unexpectedly or to find counterfeit drugs which have slipped into the supply chain. By moni-
toring every dose, they will be able to catch problems that they would have missed when only checking batches of 
medicine they suspect are degraded or counterfeit.
Stepping beyond therapeutic protein products, the system described here could be used to verify the integ-
rity of vaccines. As stated in the introduction, during one study of the vaccine distribution cold chain in India 
as much as 76% of the vaccine vials tested showed evidence of spoilage11. A system similar to the one presented 
here could be used to verify the quality of the vaccine material being used during a vaccination event. By catching 
spoiled material before it’s administered to patients the efficiency of a vaccination program can be improved. A 
more aggressive application of the system may allow a reduction in vaccine wastage. A large source of wastage 
in vaccine delivery in India has to do with the incomplete utilization of vaccines packaged in multi-dose vials8. 
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When a vaccination event is held the best practices require that at the end of the event any opened vaccine vial be 
discarded, and that any unopened vial that has been issued but unused across three vaccination sessions also be 
discarded8. This is to ensure the safety and efficacy of the vaccines. A system that can determine if the vaccine in 
an opened vial is still good could allow the re-issuing of opened vaccine vials and unused but previously issued 
vials, while at the same time catching material that should be in good condition but that may have experienced 
degradation due to an undocumented problem with storage conditions. In this application there is a direct risk 
to the patient, since it will allow the use of material that would have previously been discarded, and determining 
if the system presented here is adequate for this task will require extensive testing on a wide range of high quality 
and degraded vaccine material. Beyond protein based medicine and vaccines, there is currently need for a coun-
terfeit medicine detection tool. The World Health Organization Global Surveillance and Monitoring Systems 
report49 estimates that about US$30.5 billion is spent worldwide on substandard and falsified medical products, 
resulting in significant threats to the health of patients.
The basic approach presented in this paper, build a classifier based on the normal state of a protein and then try 
to determine when that protein is degraded, can also be applied to diagnostic applications of Raman spectroscopy. 
Particularly, this approach can be applied to the analysis of biofluids which is an active area of spectroscopy research50,51. 
Changes in the gylcosylation state of mucin proteins in mucus/sputum could be used for diagnosis of COPD52, levels 
of serum albumin can be indicative of liver failure53, and relative levels of albumin to IgG, IgA, and IgM can be markers 
for diseases of the kidneys and liver54. Mucin proteins in mucus55 along with albumin, IgG, IgA and IgM in serum56 all 
occur at concentrations high enough to be directly visible in the system presented here. In this diagnostic application 
there can be a wealth of data for the “no-disease” state from the population of healthy patients and a much smaller 
amount of data from the population with a disease. A variant detection approach could be used to identify that a change 
has occurred in the patients’ serum or mucus proteome, signaling the need for further investigation.
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